Literature DB >> 10634623

L-Arginine-nitric oxide pathway-related metabolites in the aqueous humor of diabetic patients.

L O Hattenbach1, A Allers, C Klais, F Koch, M Hecker.   

Abstract

PURPOSE: Nitric oxide (NO) is an important signal-transduction molecule that plays a significant role in the regulation of cardiovascular functions. In the L-arginine-NO pathway, NO synthase (NOS) converts L-arginine (L-Arg), the only known biologic substrate for NO formation, to NO and L-citrulline (L-Cit). Excessive NO production mediated by the inducible isoform of NOS has been implicated in the pathogenesis of various diseases. In the present study it was hypothesized that in vitreoretinal disorders such as diabetic retinopathy the production of L-Arg-NO pathway-related metabolites may be upregulated as a result of increased NO generation.
METHODS: From 20 eyes of nondiabetic subjects and 22 eyes of diabetic patients with (n = 14) and without (n = 8) diabetic retinopathy, undiluted samples of aqueous humor were drawn before cataract surgery. Levels of L-Arg, L-Cit, and the specific NOS by-product N(G)-hydroxy-L-arginine (HOArg) were measured by high-performance liquid chromatography.
RESULTS: L-Arg, L-Cit, and HOArg were detected in all aqueous humor samples from diabetic and nondiabetic patients (n = 42). Comparison of HOArg levels in nondiabetic and diabetic subjects showed significantly higher levels in diabetic patients (P = 0.002). Concentrations of HOArg were higher in samples from patients with (P = 0.005) and without diabetic retinopathy (P = 0.033) than in control subjects. No statistically significant differences were observed in L-Arg or L-Cit levels.
CONCLUSIONS: Elevated levels of HOArg in the aqueous humor of diabetic patients reflect the possible role of NO as a significant factor in the regulation of retinal vascular functions and intraocular proliferative changes in diabetes mellitus in vivo. The control of intraocular NO production may constitute a potential therapeutic approach in diabetic retinopathy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10634623

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  6 in total

1.  Contribution of nitric oxide-producing cells in normal and diabetic rat retina.

Authors:  Ryotaro Goto; Motoaki Doi; Ning Ma; Reiji Semba; Yukitaka Uji
Journal:  Jpn J Ophthalmol       Date:  2005 Sep-Oct       Impact factor: 2.447

2.  NADPH diaphorase activity in the rat retina during the early stages of experimental diabetes.

Authors:  Qing Li; Esther Zemel; Benjamin Miller; Ido Perlman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-09-02       Impact factor: 3.117

3.  Inhibition of the adrenomedullin/nitric oxide signaling pathway in early diabetic retinopathy.

Authors:  Jan J Blom; Thomas J Giove; Tara L Favazza; James D Akula; William D Eldred
Journal:  J Ocul Biol Dis Infor       Date:  2012-01-12

4.  l-Citrulline Protects from Kidney Damage in Type 1 Diabetic Mice.

Authors:  Maritza J Romero; Lin Yao; Supriya Sridhar; Anil Bhatta; Huijuan Dou; Ganesan Ramesh; Michael W Brands; David M Pollock; Ruth B Caldwell; Stephen D Cederbaum; C Alvin Head; Zsolt Bagi; Rudolf Lucas; Robert W Caldwell
Journal:  Front Immunol       Date:  2013-12-24       Impact factor: 7.561

5.  Imbalance Between Oxidative Stress and Growth Factors in Human High Myopia.

Authors:  Salvador Mérida; Vincent M Villar; Amparo Navea; Carmen Desco; María Sancho-Tello; Cristina Peris; Francisco Bosch-Morell
Journal:  Front Physiol       Date:  2020-05-14       Impact factor: 4.566

6.  Increased neuronal nitric oxide synthase activity in retinal neurons in early diabetic retinopathy.

Authors:  Thomas J Giove; Monika M Deshpande; Christine S Gagen; William D Eldred
Journal:  Mol Vis       Date:  2009-11-09       Impact factor: 2.367

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.